BIRMINGHAM, Ala., Jan. 5 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and other members of BioCryst’s management team plan to provide a corporate summary and updates regarding its clinical programs for peramivir, forodesine and BCX4208 at the J.P. Morgan 28th Annual Healthcare Conference in San Francisco on January 14, 2010 at 10:30 a.m. Pacific Time.
About BioCryst
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BioCryst Pharmaceuticals, Inc.
